Ketamine for Sickle Cell Disease

This trial tests whether early administration of ketamine (an anesthetic) can reduce hospital admissions for individuals with sickle cell disease experiencing pain. Researchers aim to determine if starting ketamine within one hour of emergency department arrival can decrease the need for hospital stays. If admission occurs, the trial also examines whether early ketamine use can reduce opioid consumption and shorten hospital stays. Suitable participants have sickle cell disease, frequently visit the emergency department due to pain, and are between 6 and 24 years old. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that ketamine is generally safe for managing pain in people with sickle cell disease. Studies have found that low doses of ketamine, which do not cause a full-body reaction, are well-tolerated by both adults and children. In these cases, ketamine reduced pain and often decreased the need for opioids, which are strong pain-relief drugs.

One study found that ketamine managed pain from sickle cell crises without causing major side effects. Another review suggested that ketamine can be used safely and effectively, especially when given in doses that do not cause feelings of disconnection from reality.

Researchers are excited about using ketamine for sickle cell disease because it offers a new approach compared to standard treatments like hydroxyurea and blood transfusions. Ketamine works differently by potentially targeting pain pathways directly, offering rapid pain relief, which is crucial for managing the severe pain crises associated with sickle cell disease. Additionally, this trial uses a single oral dose of ketamine, which could simplify administration and make it more accessible for patients compared to intravenous options.

Research has shown that ketamine might help manage pain for people with sickle cell disease. Studies have found that ketamine can reduce pain as effectively as opioids during painful episodes. Some research also suggests that ketamine can lessen the need for opioids, potentially leading to fewer side effects. In this trial, participants will receive either a single dose of oral ketamine or a placebo. Administering ketamine early has been linked to lower pain levels and reduced opioid use. Overall, evidence supports ketamine as a promising option for managing pain in patients with sickle cell disease.¹²³⁶⁷